Mustafa Cengiz1, Seren Ozenirler, Murat Kocabiyik. 1. aDepartment of Gastroenterology, Dr. A.Y. Ankara Oncology Training and Research Hospital bDepartment of Gastroenterology cDepartment of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey.
Abstract
OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease and evaluation of fibrosis is important. We aimed to investigate the utility of serum β-trophin in NAFLD and its ability to predict liver fibrosis. PATIENTS AND METHODS: Serum samples of consecutive patients with biopsy-proven NAFLD and age-matched and sex-matched healthy controls were used to measure β-trophin using ELISA. Correlations between histopathological features of NAFLD and β-trophin were analyzed. Whereas patients with fibrosis scores less than 2 were grouped in the mild fibrosis group, patients with scores of 2 or more were grouped in the significant fibrosis group. Univariate/multivariate logistic regression analyses were carried out to evaluate the independent predicting factors of liver fibrosis. Receiver operating characteristics (ROCs) were assessed to determine the best cut-off values for NAFLD and fibrosis. RESULTS: Sixty-nine patients with NAFLD and 69 healthy controls were enrolled in the study. Serum β-trophin levels were lower in NAFLD patients compared with the controls (2.34±0.06 vs. 1.94±0.09 ng/ml, respectively, P<0.001). In NAFLD, serum β-trophin was related to liver fibrosis and inflammation. The mild fibrosis group had higher serum β-trophin levels than the significant fibrosis group (2.11±0.12 vs. 1.72±0.11, respectively, P<0.001). In multivariate analysis, β-trophin remained an independent predictor of significant fibrosis (odds ratio, 0.237; 95% confidence interval, 0.059-0.949; P<0.001). ROC analysis showed that serum β-trophin was statistically significant in the identification of significant fibrosis (area under receiver operating characteristic, 0.844; 95% confidence interval, 0.718-0.970; P<0.001). The best cut-off value was 1.786, with the best sensitivity (71.43%) and specificity (95.65%). CONCLUSION: Serum β-trophin may be a potential noninvasive marker for the identification of NAFLD and significant liver fibrosis.
OBJECTIVE:Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease and evaluation of fibrosis is important. We aimed to investigate the utility of serum β-trophin in NAFLD and its ability to predict liver fibrosis. PATIENTS AND METHODS: Serum samples of consecutive patients with biopsy-proven NAFLD and age-matched and sex-matched healthy controls were used to measure β-trophin using ELISA. Correlations between histopathological features of NAFLD and β-trophin were analyzed. Whereas patients with fibrosis scores less than 2 were grouped in the mild fibrosis group, patients with scores of 2 or more were grouped in the significant fibrosis group. Univariate/multivariate logistic regression analyses were carried out to evaluate the independent predicting factors of liver fibrosis. Receiver operating characteristics (ROCs) were assessed to determine the best cut-off values for NAFLD and fibrosis. RESULTS: Sixty-nine patients with NAFLD and 69 healthy controls were enrolled in the study. Serum β-trophin levels were lower in NAFLD patients compared with the controls (2.34±0.06 vs. 1.94±0.09 ng/ml, respectively, P<0.001). In NAFLD, serum β-trophin was related to liver fibrosis and inflammation. The mild fibrosis group had higher serum β-trophin levels than the significant fibrosis group (2.11±0.12 vs. 1.72±0.11, respectively, P<0.001). In multivariate analysis, β-trophin remained an independent predictor of significant fibrosis (odds ratio, 0.237; 95% confidence interval, 0.059-0.949; P<0.001). ROC analysis showed that serum β-trophin was statistically significant in the identification of significant fibrosis (area under receiver operating characteristic, 0.844; 95% confidence interval, 0.718-0.970; P<0.001). The best cut-off value was 1.786, with the best sensitivity (71.43%) and specificity (95.65%). CONCLUSION: Serum β-trophin may be a potential noninvasive marker for the identification of NAFLD and significant liver fibrosis.
Authors: Carolina M Perdomo; Javier Gómez-Ambrosi; Sara Becerril; Víctor Valentí; Rafael Moncada; Eva M Fernández-Sáez; Leire Méndez-Giménez; Silvia Ezquerro; Victoria Catalán; Camilo Silva; Javier Escalada; Gema Frühbeck; Amaia Rodríguez Journal: Int J Mol Sci Date: 2021-11-30 Impact factor: 5.923
Authors: Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec Journal: Clin Sci (Lond) Date: 2022-09-30 Impact factor: 6.876
Authors: Federico Oldoni; Kevin Bass; Julia Kozlitina; Hannah Hudson; Lisa M Shihanian; Viktoria Gusarova; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Alper Sonmez; Teoman Dogru; Cemal Nuri Ercin; Halil Genc; Gurkan Celebi; Hasan Gurel; Serkan Tapan; Ali Fuat Cicek; Cem Barcin; Cem Haymana; Ali Kirik; Manfredi Rizzo Journal: Metabolites Date: 2021-06-28